ABC | Volume 111, Nº1, July 2018

Original Article Kalkan et al Adropin and Irisin Arq Bras Cardiol. 2018; 111(1):39-47 1. Hunt SA, AbrahamWT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al; American College of Cardiology; AmericanHeart Association Task Force on PracticeGuidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/ AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):e154-235. 2. Pureza V, Florea VG. Mechanisms for cachexia in heart failure. Curr Heart Fail Rep. 2013;10(4):307-14. 3. von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res. 2007;73(2):298-309. 4. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96(2):526-34. 5. Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al. Identification of adropin as a secreted factor linking dietarymacronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008;8(6):468-81. 6. Aydin S. Three newplayers in energy regulation: preptin, adropin and irisin. Peptides. 2014 Jun;56:94-110. 7. Lian W, Gu X, Qin Y, Zheng X. Elevated plasma levels of adropin in heart failure patients. Intern Med. 2011;50(15):1523-7. 8. Wu L, Fang J, Chen L, Zhao Z, Luo Y, Lin C, et al. Low serum adropin is associatedwith coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med. 2014;52(5):751-8. 9. Topuz M, Celik A, Aslantas T, Demir AK, Aydin S, Aydin S. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. J Investig Med. 2013;61(8):1161-4. 10. Celik A, Balin M, Kobat MA, Erdem K, Baydas A, Bulut M, et al. Deficiency of a new protein associated with cardiac syndrome X; called adropin. Cardiovasc Ther. 2013;31(3):174-8. 11. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1- dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463-8. 12. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, BöhmM, Dickstein K, etal.ESCCommittee forPracticeGuidelines.ESCguidelines forthediagnosis and treatment of acute and chronic heart failure 2012: The Task Force for theDiagnosis and Treatment of Acute and ChronicHeart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14(8):803-69. Erratum in: Eur J Heart Fail. 2013;15(3):361-2. 13. OkoshiMP,RomeiroFG,PaivaSA,OkoshiK.Heart failure-inducedcachexia. Arq Bras Cardiol. 2013;100(5):476-82. 14. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol. 2012;19(4):585-667. 15. Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Manuel Gómez J, et al. Bioelectrical impedance analysis: utilization in clinical practice. Clin Nutr. 2004;23(6):1430-53. 16. Pardo M, Crujeiras AB, Amil M, Aquera Z, Jimenez-Murcia S, Botella C, et al. Assocation of irisin with fat mass, resting energy expenditure, and daily activity in conditions of extreme body mass index. Int J Endocrinol. 2014;2014:857270. Doi 10.1155/2014/857270. Epub 2014 Apr 22. 17. InvernizziM,CardaS,CisariC;Società Italianaper loStudiodellaSarcopenia e della Disabilità Muscolo-Scheletrica (SISDIM). Possible synergism of physical exercise and ghrelin-agonists in patients with cachexia associated with chronic heart failure. Aging Clin Exp Res. 2014;26(4):341-51. 18. Doehner W, Frenneaux M, Anker SD. Metabolic impairment in heart failure: the myocardial and systemic perspective. J Am Coll Cardiol. 2014;64(13):1388-400. 19. Szabó T, Scherbakov N, Sandek A, Kung T, von Haehling S, Lainscak M, et al. Plasma adiponectin in heart failure with andwithout cachexia: catabolic signal linking catabolism, symptomatic status, and prognosis. Nutr Metab Cardiovasc Dis. 2014;24(1):50-6. 20. Von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther. 2009;121(3):227-52. 21. Sente T, Van Berendocks AM, Hoymans VY, Vrints CJ. Adiponectin resistance in skelatal muscle: pathophysiological implications in chronic heart failure. J Cachexia Sarcopenia Muscle. 2016;7(3):261-74. 22. AshrafianH,FrenneauxMP,OpieLH.Metabolicmechanisms inheart failure. Circulation. 2007;116(4):434-48. References Author contributions Conception and design of the research: Kalkan AK, Cakmak HA, Aydin S, Celik A; Acquisition of data: Kalkan AK, Uzun F, Tasbulak O, Diker VO; Analysis and interpretation of the data: Kalkan AK, Cakmak HA, Erturk M, Tasbulak O, Diker VO; Statistical analysis: Kalkan AK, Erturk M, Uzun F, Celik A; Obtaining financing: Kalkan AK, Aydin S, Celik A; Writing of the manuscript: Kalkan AK, Erturk M, Kalkan KE, Aydin S, Celik A; Critical revision of the manuscript for intellectual content: Kalkan AK, Kalkan KE. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding There were no external funding sources for this study. Study Association This study is not associatedwith any thesis or dissertationwork. Ethics approval and consent to participate This study was approved by the Ethics Committee of the Mehmet Akif Ersoy Thoracic and Cardiovascular Disease Education and Training Hospital under the protocol number 2015-23. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study. 46